Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Edison Oncology
Menlo Park, California, USAedisononcology.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Edison Oncology has reported promising interim data from its ongoing multicenter Phase I/IIa clinical trial of Orotecan® in recurrent pediatric cancers. The oral formulation aims to improve quality of life by enabling at-home treatment compared to standard intravenous irinotecan regimens. EO1001 has entered first-in-human trials targeting multiple ErbB mutations with potential applications across several solid tumor types including those with CNS involvement.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculesOral formulations (e.g., Orotecan)Tyrosine kinase inhibitors (TKIs)
- Industry
- Biotech
02
Partnerships
Apollomics Inc.: Global development/commercialization partnership for EO1001 except Mainland China/Hong Kong/Taiwan.Rakovina Therapeutics Inc.: Minority interest and assignment of DNA-damage response inhibitor assets.
Beyond the preview
Go deeper on Edison Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Edison Oncology.